Zilico Company
Zilico is developing the next generation of cancer diagnostics that will provide real-time diagnosis for cervical cancer and reduce the inherent subjectivity of current methods. Two applications are under development: the first for the referral market and the second for the screening market.
Investors
Headquarters:
Manchester, Manchester, United Kingdom
Last Funding Type:
Corporate Round
Investors Number:
8
Last Funding Date:
2018-02-04
Employee Number:
11-50
Total Funding:
$24 M
Founded Date:
2006-01-01
Technology:
Biomarkers of Female Cancers
Estimated Revenue:
$1M to $10M
Industry:
Longevity
Funding Status:
Corporate Round